Alpha7 Nicotinic Receptors and MAP Kinase in AD Models

About the Research Project
Program
Award Type
Standard
Award Amount
$200,000
Active Dates
April 01, 2002 - March 31, 2004
Grant ID
A2002001
Summary
Early stage Alzheimer’s disease is generally observed as hippocampal dysfunction with the inability of the brain to consolidate short-term into long-term memories. These memory deficits are typically present before any generalized dementia or overall cognitive decline is observed. Dr. Sweatt hypothesizes that for the early stages of AD, which are characterized by subtle deficits in memory consolidation; there will be abnormalities in the normal biochemical machinery that underlies memory. He suggests that the MAP kinase signaling cascade plays a critical role in learning and memory. He is examining the transgenic mouse model of AD for MAP kinase signaling defects. He will also examine how the amyloid beta peptide is linked to the MAP kinase cascade. Preliminary results suggest that a receptor for amyloid beta peptide on the cell surface of neurons is the alpha7 nicotinic acetylcholine receptor. Dr. Sweatt will use genetic approaches to examine whether deletion of the alpha7 receptor gene leads to amelioration of memory deficits exhibited in transgenic mice with AD and decreases in biochemical markers. The identification of the alpha 7 receptor involvement in AD allows for the future study of agents that block the receptor as potential therapeutics for AD.
Grants
Related Grants
Alzheimer's Disease Research
Regulatory Mechanisms Underlying Endosomal Targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Olav Andersen, PhD
Regulatory Mechanisms Underlying Endosomal Targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026

Principal Investigator
Olav Andersen, PhD
Alzheimer's Disease Research
The Role of DYRK1A in Altered Microglia Biology in a Cellular Model of Alzheimer’s Disease in Down Syndrome
Active Dates
January 01, 2025 - December 31, 2027
Principal Investigator
Frances Wiseman, PhD
The Role of DYRK1A in Altered Microglia Biology in a Cellular Model of Alzheimer’s Disease in Down Syndrome
Active Dates
January 01, 2025 - December 31, 2027

Principal Investigator
Frances Wiseman, PhD
Alzheimer's Disease Research
Synergistic Effects of Biological Sex and Sleep Loss in an AD Mouse Model
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Mallar Chakravarty, PhD
Synergistic Effects of Biological Sex and Sleep Loss in an AD Mouse Model
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Mallar Chakravarty, PhD